Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

doi:10.1016/S0140-6736(95)91150-2

The Lancet

Volume 345, Issue 8941, 7 January 1995, Pages 9-13

https://doi.org/10.1016/S0140-6736(95)91150-2 Get rights and content

Abstract

Summary

Reactivation of Epstein-Barr virus (EBV) after bone-marrow transplantation leads in many cases to lymphoproliferative disease that responds poorly to standard therapy and is usually fatal. To prevent or control this complication, we prepared EBV-specific cytotoxic T-lymphocyte (CTL) lines from donor leucocytes and infused them into ten allograft recipients.

Three of the patients had shown signs of EBV reactivation, with or without overt lymphoproliferation, and the others received CTL infusions as prophylaxis. No patient developed any complication that could be attributed to the CTL infusions. In the three patients with EBV reactivation, EBV DNA concentrations (measured by semiquantitative polymerase chain reaction [PCR]), which had increased 1000-fold or more, returned to the control range within 3-4 weeks of immunotherapy. The most striking consequence was the resolution of immunoblastic lymphoma in a 17-year-old patient who received four CTL infusions (two 1×10⁷/m² and two 5×10⁷/m²). Because the CTL had been genetically marked before infusion, we were able to show by PCR analysis that they persisted for 10 weeks after administration.

EBV-specific donor-type T-cell lines seem to offer safe and effective therapy for control of EBV-associated lymphoproliferation.

References (30)

D. Joske et al.
Epstein-Barr virus in Lymphomas: a review
Blood Rev
(1993)
G. Klein
Epstein-Barr virus strategy in normal and neoplastic B cells
Cell
(1994)
Mk Brenner et al.
Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
Lancet
(1993)
Mj Boyle et al.
Sub types of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma
Blood
(1991)
U. Zimber et al.
Geographical prevalence of two types of Epstein-Barr virus
Virology
(1986)
A. Savoie et al.
Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease
Blood
(1994)
Sa Riddler et al.
Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody response are associated with the development of post-transplant lymphoproliferative disease in solid-organ transplant recipients
Blood
(1994)
He Heslop et al.
Epstein-Barr infection after bone marrow transplantation
Blood
(1994)
Hj Kolb et al.
Donor leucocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant recipients
Blood
(1990)
F. van Rhee et al.
Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse
Blood
(1994)

As Duncombe et al.

Bone marrow transplant recipients have defective MHC-unrestricted cytotooxic response against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1)

Blood

(1992)

Se Strauss et al.

Epstein-Barr virus infections: biology, pathogenesis and management

Ann Intern Med

(1992)

Af List et al.

Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein Barr virus

J Clin Oncol

(1987)

Ki Cohen

Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency

Proc Natl Acad Sci USA

(1991)

Cited by (1036)

Silencing of PD-1 combined with EBV-specific killer T cells for the treatment of EBV-associated B lymphoma
2024, Translational Oncology
Epstein-Barr Virus (EBV) infection is closely associated with the development of lymphoma, as it plays a significant role in the malignant transformation of lymphocytes. The expression of programmed death-1 (PD-1), which binds to PD-L1 in tumor cells, can lead to immune evasion by lymphoma cells and promote tumor progression. In this study, immortalized B lymphoblastoid cell lines (B-LCLs) positive for EBV-specific proteins were established from human peripheral mononuclear cells (PBMCs) using EBV induction along with CpG-ODN 2006 and cyclosporin A. EBV-specific T cells (EBVST) were generated by multiple immunizations of CD3⁺ T lymphocytes using irradiated B-LCLs. Flow cytometry analysis confirmed the activation of EBVST through the detection of CD3⁺, CD4⁺, and CD8⁺ markers. Co-incubation of EBVST with EBV-positive B lymphocyte cell lines resulted in the secretion of perforin by EBVST, leading to granzyme B-mediated cell death and an increase in LDH levels. Silencing PD-1 in EBVST cells enhanced perforin production, increased granzyme B release, and upregulated cell death in co-incubated B lymphocytes. In a nude mice tumor transplantation model, silencing PD-1 in combination with EBV-specific killer T cells exhibited the maximum inhibition of B-lymphoblastoma. This treatment upregulated the expression of proteins associated with apoptosis and immune response, while inhibiting anti-apoptotic protein expression in tumor tissues. Silencing PD-1 also increased the infiltration of EBV-specific killer T cells in the tumor tissues. Overall, PD-1 silencing enhanced the tumor targeting effect of EBV-specific killer T cells on EBV-infected B lymphocytes and attenuated the immune escape effect mediated by the PD-1 pathway.
Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients
2024, Cytotherapy
Deficits in T cell immunity translate into increased risk of severe viral infection in recipients of solid organ and hematopoietic cell transplants. Thus, therapeutic strategies that employ the adoptive transfer of virus-specific T cells are being clinically investigated to treat and prevent viral diseases in these highly immunocompromised patients. Posoleucel is an off-the-shelf multivirus-specific T cell investigational product for the treatment and prevention of infections due to adenovirus, BK virus, cytomegalovirus, Epstein–Barr virus, human herpesvirus 6 or JC virus.
Herein we perform extensive characterization of the phenotype and functional profile of posoleucel to illustrate the cellular properties that may contribute to its in vivo activity.
Our results demonstrate that posoleucel is enriched for central and effector memory CD4⁺ and CD8⁺ T cells with specificity for posoleucel target viruses and expressing a broad repertoire of T cell receptors. Antigen-driven upregulation of cell-surface molecules and production of cytokine and effector molecules indicative of proliferation, co-stimulation, and cytolytic potential demonstrate the specificity of posoleucel and its potential to mount a broad, polyfunctional, and effective Th1-polarized antiviral response upon viral exposure. We also show the low risk for off-target and nonspecific effects as evidenced by the enrichment of posoleucel in memory T cells, low frequency of naive T cells, and lack of demonstrated alloreactivity in vitro. The efficacy of posoleucel is being explored in four placebo-controlled clinical trials in transplant recipients to treat and prevent viral infections (NCT05179057, NCT05305040, NCT04390113, NCT04605484).
Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review
2024, Seminars in Nephrology
Cancer is one of the most devastating complications of kidney transplantation and constitutes one of the leading causes of morbidity and mortality among solid organ transplantation (SOT) recipients. Immunosuppression, although effective in preventing allograft rejection, inherently inhibits immune surveillance against oncogenic viral infections and malignancy. Adoptive cell therapy, particularly immune effector cell therapy, has long been a modality of interest in both cancer and transplantation, though has only recently stepped into the spotlight with the development of virus-specific T-cell therapy and chimeric antigen receptor T-cell therapy. Although these modalities are best described in hematopoietic cell transplantation and hematologic malignancies, their potential application in the SOT setting may hold tremendous promise for those with limited therapeutic options. In this review, we provide a brief overview of the development of adoptive cell therapies with a focus on virus-specific T-cell therapy and chimeric antigen receptor T-cell therapy. We also describe the current experience of these therapies in the SOT setting as well as the challenges in their application and future directions in their development.
MHC tetramer technology: Exploring T cell biology in health and disease
2024, Advances in Protein Chemistry and Structural Biology
Major histocompatibility complex (MHC) tetramers stand as formidable tools within T cell biology, facilitating the exploration and comprehension of immune responses. These artificial molecules, comprising four bound MHC molecules, typically with a specified peptide and a fluorescent label, play a pivotal role in characterizing T cell subsets, monitoring clonal expansion, and unraveling T cell dynamics during responses to infections or immunotherapies. Beyond their applications in T cell biology, MHC tetramers prove valuable in investigating a spectrum of diseases such as infectious diseases, autoimmune disorders, and cancers. Their instrumental role extends to vaccine research and development. Notably, when appropriately configured, tetramers transcend T cell biology research and find utility in exploring natural killer T cells and contributing to specific T cell clonal deletions.
Can academic structures improve access to CAR-T cells?
2024, Bulletin du Cancer
En France, à ce jour, les unités de thérapie cellulaire hospitalière n’ont pas d’autorisation à produire en routine des lymphocytes T Chimeric antigen receptor (CAR-T cells) qui seraient alors qualifiés de CAR-T cells académiques. Les CAR-T cells sont qualifiés de médicament de thérapie innovante et correspondent à des lymphocytes T modifiés génétiquement ex vivo. Le procédé de production de CAR-T cells est complexe et nécessite une expertise scientifique et technique pour répondre aux critères d’acceptation du système qualité pharmaceutique. La méthode la plus utilisée pour modifier génétiquement les lymphocytes T est la transduction virale (lentivirale ou rétrovirale) nécessitant au préalable l’accès à un lot de vecteur viral de grade Bonne Pratique de Fabrication (BPF). Du fait de son coût, ce réactif est le principal facteur limitant pour développer des CAR-T cells. Un CAR-T cell produit par un industriel est onéreux (environ 350 000 € l’injection) et le temps de mise à disposition au clinicien par le fabricant peut aller de trois à cinq semaines. En répondant aux enjeux économiques et écologiques, les structures académiques peuvent-elles permettre une amélioration de l’accessibilité aux CAR-T cells ? Dans cet article, nous présentons des éléments nécessaires pour la faisabilité de la mise en place d’une production de CAR-T cells dans une structure académique.
In France, hospital cell therapy units have not been authorised to routinely produce chimeric antigen receptor T lymphocytes (CAR-T cells), which would then be referred to as academic CAR-T cells. CAR-T cells are classified as advanced therapy medicinal products and correspond to genetically modified T lymphocytes ex vivo. The CAR-T cell production process is complex and requires scientific and technical expertise to meet the acceptance criteria of the pharmaceutical quality system. The most commonly used method for genetically modifying T lymphocytes is viral transduction (lentiviral or retroviral), which requires prior access to a batch of good manufacturing practice (GMP) grade viral vector. Because of its cost, this reagent is the main limiting factor for developing CAR-T cells. A CAR-T cell produced by an industrial company is expensive (around €350,000 per injection) and the time taken by the manufacturer to make it available to the clinician can vary from three to five weeks. By meeting the economic and ecological challenges, can academic structures improve access to CAR-T cells? In this article, we present the elements necessary for the feasibility of setting up CAR-T cell production in an academic structure.
How I treat posttransplant lymphoproliferative disorder
2023, Blood
Posttransplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid organ transplant and hematopoietic stem cell transplant (HSCT). Given the heterogeneity of PTLD and the risk of infectious complications in patients with immunosuppression, the treatment of this disease remains challenging. Monomorphic PTLD and lymphoma of B-cell origin account for the majority of cases. Treatment strategies for PTLD consist of response-adapted, risk-stratified methods using immunosuppression reduction, immunotherapy, and/or chemotherapy. With this approach, ∼25% of the patients do not need chemotherapy. Outcomes for patients with high risk or those who do not respond to frontline therapies remain dismal, and novel treatments are needed in this setting. PTLD is associated with Epstein-Barr virus (EBV) infection in 60% to 80% of cases, making EBV-directed therapy an attractive treatment modality. Recently, the introduction of adoptive immunotherapies has become a promising option for refractory cases; hopefully, these treatment strategies can be used as earlier lines of therapy in the future.

View all citing articles on Scopus

View full text

ArticlesUse of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

Abstract

Blood Rev

Cell

Lancet

Blood

Virology

Blood

Blood

Blood

Blood

Blood

Blood

Epstein-Barr virus infections: biology, pathogenesis and management

Ann Intern Med

Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein Barr virus

J Clin Oncol

Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency

Proc Natl Acad Sci USA

Articles
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation